HEALTH‐RELATED QUALITY OF LIFE (HRQoL) IN RELAPSED/REFRACTORY (R/R) INDOLENT NHL IN THE PHASE 3 AUGMENT TRIAL OF RITUXIMAB (R) PLUS LENALIDOMIDE (R2) VERSUS R PLUS PLACEBO. (12th June 2019)

• Record Type: Journal Article
• Authors: Leonard, J.P.; Trněny, M.; Izutsu, K.; Fowler, N.H.; Hong, X.; Zhang, H.; Offner, F.; Scheliga, A.; Nowakowski, G.; Pinto, A.; Re, F.; Fogliatto, L.M.; Scheinberg, P.; Flinn, I.W.; Moreira, C.; Tabah, A.; Abouzaid, S.; Kalambakas, S.; Fustier, P.; Wu, C.; Gribben, J.G.
• Is Part Of: Hematological oncology. Volume 37(2019)Supplement 2
• Page Start: 232
• Page End: 234
• Publication Date: 2019-06-12
• Subjects: Hematological oncology -- Periodicals; Hematology; Medical Oncology; 616.99418005
• DOI: 10.1002/hon.45_2630
• Languages: English
• ISSNs: 0278-0232